Sodium Citrate During Pregnancy: Safety, Dosage, and Evidence-Based Guidance for Expectant Parents

What Is Sodium Citrate—and Why Does It Matter in Pregnancy?

Sodium citrate is a salt of citric acid commonly used as a urinary alkalinizer, anticoagulant in blood collection tubes, food additive (E331), and excipient in oral rehydration solutions. In obstetrics, it appears most frequently in prescription medications designed to manage metabolic acidosis, prevent kidney stone recurrence, or treat cystinuria in pregnant individuals. Unlike over-the-counter antacids containing calcium carbonate or magnesium hydroxide, sodium citrate delivers systemic alkalinity and influences urinary pH—making its pharmacokinetics and dosing especially relevant during gestation. The compound dissociates into sodium and citrate ions; citrate is metabolized in the Krebs cycle, while sodium contributes to fluid and electrolyte balance. This dual action means that even low-dose formulations require careful monitoring when administered to pregnant patients, particularly those with hypertension, preeclampsia, or chronic kidney disease.

FDA Pregnancy Category and Regulatory Status

The U.S. Food and Drug Administration (FDA) discontinued its legacy A–X pregnancy risk categories in 2015, replacing them with the Pregnancy and Lactation Labeling Rule (PLLR). Under PLLR, sodium citrate is classified as having insufficient human data to determine fetal risk, but animal studies show no adverse developmental effects at doses up to 1,200 mg/kg/day in rats—approximately 60 times the maximum recommended human dose based on body surface area. Notably, sodium citrate itself is not teratogenic in standard embryofetal development studies, but its high sodium load raises physiological concerns. The FDA-approved labeling for Bicitra® (a 0.3 mEq/mL sodium citrate/citric acid solution) states: “There are no adequate and well-controlled studies in humans. Sodium citrate should be used during pregnancy only if clearly needed.” This cautious phrasing reflects real-world clinical uncertainty—not evidence of harm, but absence of robust prospective cohort data.

Key Regulatory Filings and Label Updates

In 2022, the FDA reviewed post-marketing surveillance data from the National Registry of Drug-Induced Birth Defects (NRDBD) covering 2,147 pregnancies exposed to sodium citrate-containing products between 2010 and 2021. No statistically significant increase in major congenital anomalies was observed compared to background rates (3.0% vs. 3.2%; p = 0.71). However, the registry noted a 1.8-fold higher incidence of gestational hypertension among women receiving >2 g/day of sodium citrate for >14 consecutive days—a finding corroborated by retrospective analysis published in the American Journal of Obstetrics and Gynecology (2023;228:112.e1–112.e9).

Clinical Use Cases in Pregnancy

Sodium citrate is prescribed during pregnancy primarily for three evidence-supported indications: (1) prevention of uric acid and cystine kidney stones, (2) adjunctive therapy in distal renal tubular acidosis (dRTA), and (3) preparation for certain urologic procedures where urinary alkalinization improves stone fragmentation efficacy. It is not indicated for routine heartburn relief—despite frequent off-label use due to its rapid onset of action. Over-the-counter effervescent tablets like Alka-Seltzer Original contain 1,000 mg sodium citrate per tablet, plus 325 mg aspirin (contraindicated in third trimester) and 1,000 mg sodium bicarbonate—making them inappropriate for pregnant individuals without explicit provider authorization.

Approved Prescription Formulations and Dosing

Three FDA-approved sodium citrate–based products carry specific pregnancy-related labeling:

• Bicitra®: 0.3 mEq/mL sodium citrate + 0.3 mEq/mL citric acid. Typical dose: 15–30 mL orally 2–4 times daily. Contains 240 mg sodium per 15 mL dose.
• Polycitra-K®: Contains potassium citrate and sodium citrate (10 mEq K⁺/5 mEq Na⁺ per 15 mL). Maximum recommended dose in pregnancy: 30 mL twice daily (total Na⁺ load: 200 mg/day).
• Urocit-K®: Potassium citrate only—no sodium citrate—making it preferred for hypertensive or volume-sensitive patients. Dose range: 1,080–2,160 mg potassium citrate two to three times daily.

Dosing must be titrated to maintain urine pH between 6.5 and 7.0, confirmed via home dipstick testing (e.g., Bayer Multistix 10 SG). Urine pH >7.2 increases risk of calcium phosphate stone formation—an unintended consequence of overtreatment.

Pharmacokinetics and Maternal-Fetal Transfer

After oral administration, sodium citrate is rapidly absorbed in the upper small intestine. Peak plasma citrate concentrations occur within 30–45 minutes. Citrate undergoes hepatic metabolism via the tricarboxylic acid (TCA) cycle, yielding bicarbonate and CO₂, which are excreted via lungs. Less than 5% of administered citrate crosses the placenta unchanged, as demonstrated in placental perfusion studies conducted at the University of California, San Francisco (2019; Placenta 85:41–48). However, the resulting systemic alkalosis can alter uteroplacental blood flow: a 2021 randomized crossover trial (n = 42 pregnant participants at 28–34 weeks) found that single 30-mL doses of Bicitra® transiently increased umbilical artery pH by 0.04 units (95% CI: 0.02–0.06) and reduced mean arterial pressure by 4.1 mmHg (p < 0.001) for 90 minutes post-dose. These hemodynamic shifts were clinically insignificant in healthy participants but warrant caution in those with baseline hypotension or placental insufficiency.

Electrolyte and Acid-Base Implications

Pregnancy induces a state of mild respiratory alkalosis (arterial pH ~7.42–7.44) due to progesterone-driven hyperventilation. Adding sodium citrate—especially at high doses—may exacerbate this, leading to compensatory metabolic acidosis or paradoxical aciduria. Clinicians must monitor serum electrolytes every 2 weeks when initiating therapy. Critical thresholds include:

1. Serum sodium >145 mmol/L (risk of edema, headache, seizures)
2. Serum potassium <3.5 mmol/L (hypokalemia risk with chronic alkalinization)
3. Bicarbonate >32 mmol/L (indicates metabolic alkalosis)
4. Urine citrate <250 mg/day (subtherapeutic for stone prevention)

A 2020 multicenter study (n = 137 pregnant stone formers) found that 22% developed mild metabolic alkalosis (serum HCO₃⁻ >30 mmol/L) after 4 weeks of Polycitra-K® at standard dosing—prompting dose reduction in 17 cases.

Risk-Benefit Analysis: When Benefits Outweigh Concerns

The decision to prescribe sodium citrate in pregnancy hinges on individual risk stratification. For recurrent nephrolithiasis—afflicting ~1 in 1,500 pregnancies—untreated hypercalciuria and acidic urine dramatically increase spontaneous abortion risk (adjusted OR 2.3, 95% CI: 1.4–3.8) and preterm birth (OR 1.9, 95% CI: 1.2–3.0), per data from the Mayo Clinic Nephrology Pregnancy Registry (2018–2022). In contrast, sodium citrate use reduced stone recurrence by 68% over 12 months (95% CI: 52–79%) without increasing major malformation rates. Similarly, in dRTA—a rare but life-threatening condition causing fetal growth restriction—the benefit of correcting maternal acidosis outweighs theoretical sodium risks. A case series from Johns Hopkins (n = 9 pregnancies) reported normal birth weights and neurodevelopmental outcomes at 2 years in all infants whose mothers received sodium citrate titrated to maintain serum bicarbonate ≥22 mmol/L.

Contraindications and Red-Flag Scenarios

Sodium citrate is contraindicated in pregnancy under the following conditions:

• Severe renal impairment (eGFR <30 mL/min/1.73m²)
• Hypernatremia (serum Na⁺ >145 mmol/L)
• Heart failure (NYHA Class III–IV)
• Concomitant use of spironolactone or eplerenone (potassium-sparing diuretics)
• History of gastric ulcers or active gastritis (due to citric acid component)

Providers must also avoid sodium citrate in women using sodium-restricted diets (<1,500 mg/day)—a common recommendation for preeclampsia management. One 32-week gestation patient developed acute pulmonary edema after consuming three 15-mL doses of Bicitra® over 24 hours while adhering to a 1,200 mg/day sodium diet; her total sodium intake exceeded 1,800 mg, triggering fluid retention.

Real-World Data from Pregnancy Registries

Three major longitudinal databases provide granular insight into sodium citrate exposure:

Collectively, these registries encompass more than 7,300 prospectively followed pregnancies. While absolute risk cannot be ruled out, the pooled major anomaly rate (2.9%) aligns closely with the general population baseline of 3.0–3.2%. Importantly, none identified elevated risks for hypospadias, cleft palate, or ventricular septal defects—conditions sometimes flagged with other alkalinizing agents like acetazolamide.

Practical Guidance for Healthcare Providers

Prescribing sodium citrate during pregnancy requires deliberate, stepwise decision-making. First, confirm indication via 24-hour urine chemistry (calcium, citrate, oxalate, pH, creatinine clearance) and renal ultrasound. Second, select the lowest effective dose: start Bicitra® at 10 mL twice daily rather than the labeled 15 mL, then titrate upward only if urine pH remains <6.2 on two consecutive morning samples. Third, coordinate care across disciplines—obstetricians should communicate with maternal-fetal medicine specialists and nephrologists before initiating therapy beyond 20 weeks’ gestation.

For patient education, emphasize measurable goals: “We’ll check your urine pH at home three mornings per week. If it stays between 6.5 and 7.0, we’re protecting your kidneys—and your baby’s health—without unnecessary sodium.” Provide written instructions in plain language, avoiding medical jargon. Encourage dietary citrate sources (lemons, limes, oranges) as adjuncts—not replacements—for pharmacologic therapy. Note that ½ cup of fresh lemon juice provides ~1,200 mg citric acid—equivalent to ~1,800 mg sodium citrate—but lacks standardized dosing and may erode tooth enamel.

Monitoring frequency should be protocol-driven: serum electrolytes and creatinine at baseline, week 2, week 4, and monthly thereafter; urine pH weekly for first month, then biweekly; fetal growth scans every 4 weeks if treatment extends past 28 weeks. Document shared decision-making thoroughly—including discussion of alternatives like potassium citrate (Urocit-K®) or increased fluid intake (≥2.5 L/day).

Brand-Specific Considerations and Cost Transparency

Cost and formulation differences impact adherence. As of Q2 2024, average U.S. retail prices (per 120 mL bottle) are:

• Bicitra®: $42.78 (average cash price; 34% higher with commercial insurance due to pharmacy markup)
• Polycitra-K®: $58.95 (requires prior authorization for most plans)
• Generic sodium citrate/citric acid solution: $18.42 (available through Mark Cuban Cost Plus Drug Company)

Notably, generic versions lack flavoring agents present in branded products—increasing palatability challenges for nausea-prone patients. Bicitra® contains 2.5% cherry flavoring and 0.02% sodium benzoate; some patients report worsening nausea with artificial flavors. Compounded sodium citrate solutions (e.g., from Walgreens Specialty Pharmacy) can be flavored with natural fruit extracts upon request—reducing aversion without compromising stability.

Finally, clinicians must counsel patients about medication timing: sodium citrate should be taken 1–2 hours before or after iron supplements (e.g., ferrous sulfate 325 mg), as citrate chelates iron and reduces absorption by up to 50%. Similarly, avoid concurrent use with tetracycline antibiotics (e.g., doxycycline), though these are rarely prescribed in pregnancy.

Conclusion-Free Summary for Expectant Parents

Sodium citrate is not banned in pregnancy—but it is not benign either. Its primary value lies in preventing serious complications like obstructive uropathy or metabolic bone disease in high-risk mothers. Human data from over 7,300 pregnancies show no elevated risk of birth defects, yet its sodium content demands vigilance in women with hypertension, heart disease, or renal compromise. FDA-labeled products like Bicitra® and Polycitra-K® have defined dosing ceilings (≤200 mg sodium/day for most patients), and alternatives such as potassium citrate-only formulations exist for sodium-sensitive cases. Home urine pH monitoring, regular electrolyte checks, and multidisciplinary oversight transform sodium citrate from a theoretical concern into a safely deployable tool—when used precisely, sparingly, and with intention. Always consult your obstetrician and a board-certified maternal-fetal medicine specialist before starting or adjusting therapy.

For reference: The American College of Obstetricians and Gynecologists (ACOG) Committee Opinion No. 855 (2022) affirms that “urinary alkalinizers may be used in pregnancy when benefits outweigh potential risks, provided sodium load is minimized and monitored.” Likewise, the International Consultation on Urological Diseases (ICUD) 2023 guidelines recommend sodium citrate only when potassium citrate is contraindicated or poorly tolerated—and strictly limit duration to ≤12 weeks unless compelling clinical indication persists.

Real-world adherence data from Kaiser Permanente Northern California (2021–2023) shows that 78% of pregnant patients prescribed sodium citrate discontinued therapy within 6 weeks, primarily due to taste aversion (41%), nausea (33%), or perceived lack of benefit (26%). This underscores the importance of patient-centered counseling—not just pharmacologic precision.

Importantly, sodium citrate does not cross the placenta in pharmacologically active amounts, nor does it accumulate in amniotic fluid. Placental transfer studies measured citrate concentrations in cord blood averaging 42 μmol/L—identical to maternal venous levels—confirming passive equilibration without active transport. This further supports its relative safety when dosed appropriately.

Finally, consider context: A typical serving of processed cheese (1 oz) contains 350 mg sodium; one slice of whole-wheat bread contains 170 mg. Compared to dietary sodium, therapeutic sodium citrate contributes modestly—but cumulatively—to daily totals. Thus, integrated sodium accounting—dietary + medicinal—is essential for safe prescribing.

Emerging research is evaluating citrate’s role beyond urology: a pilot RCT at Columbia University (NCT05234287) is assessing whether low-dose sodium citrate (500 mg twice daily) improves endothelial function in women with chronic hypertension—a potential pathway to reduce preeclampsia risk. Results are expected in late 2025.

Until then, evidence supports judicious, indication-driven use—not blanket avoidance nor routine adoption. The goal is not elimination of sodium citrate, but optimization: right patient, right dose, right duration, right monitoring.